{"name":"Medsenic","slug":"medsenic","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Arsenic Trioxide Injectable Solution","genericName":"Arsenic Trioxide Injectable Solution","slug":"arsenic-trioxide-injectable-solution","indication":"Acute promyelocytic leukemia (APL)","status":"phase_2"}]}],"pipeline":[{"name":"Arsenic Trioxide Injectable Solution","genericName":"Arsenic Trioxide Injectable Solution","slug":"arsenic-trioxide-injectable-solution","phase":"phase_2","mechanism":"Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation.","indications":["Acute promyelocytic leukemia (APL)","Relapsed or refractory APL"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQNUxjM2JuU1JteV9UZXJjVUl4YWQ1MWtsZHl5dGdURmZtY0JKZ1dKaHNvdWR4SXpqZmRMMTVEc3ZEVVJ6LVNJa0kxNUpvLVpiVlFoZzloMjh2ZG1sU0dWbkhsVG1sS29vRXdpZ1dpUEZIb1hUTmgzaXluVzkxTmdOUTBqcFE?oc=5","date":"2023-06-19","type":"pipeline","source":"pharmaphorum","summary":"BioSenic slumps as it sidelines bone repair therapy - pharmaphorum","headline":"BioSenic slumps as it sidelines bone repair therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOQU93OGRfLUhyanZzNWdaVVR3b2REYS1wa1VBQURDUWQzYVZFODlnNzZ4QkhSVTFqYWhuUkhtZEZqS2RIME90YmtScFFmb2JBQmRUZGgxaWdaYmR6QnNGT1RFX1p2cVE1dl9oZXRaWTZPSWNUTlp4SFh2Nm8wTXNDQThn?oc=5","date":"2023-05-30","type":"pipeline","source":"Pharmaceutical Technology","summary":"Medsenic amends licence agreement with Phebra for OATO - Pharmaceutical Technology","headline":"Medsenic amends licence agreement with Phebra for OATO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxObUV2cDZ5VEJjMzhBelpFdU1XZzJVOUk3bTlGaF9nckpzbHJvZDBXbkJsOTRoSmkzVHpVd09DLWdHd1VheFVNWG1zN1l4WGxuQUZiNGNPU2J4N0IzMFQ3R1didUNnN1ppQWJlbmYzVnRPWTBkMlF3dXVCSWtaTlM5T0RyMVduc2V5clpsaWZRbjR1TDZMXzFxa0hUVDQ0LTB1Y0c4eXBGaFpqZTBpbDlDOGtIbzVYX3Z5TnNKdQ?oc=5","date":"2022-12-19","type":"pipeline","source":"Fierce Pharma","summary":"2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding - Fierce Pharma","headline":"2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOa01RSlB0Z2htYWc4ZXN0ZU01QzVFaUZSYkVrWmVMZ21lMVA3QzBxc3FfU0U4Z2o5eHJQR3l5aXN4OEU4ZFp4dkYwSE0wODVHZHNxU25ZUUx5NERMUDhBemF5VmZoSXVCYnhlRm8wVmV1aU9QTmhyWmpfOWY0dkNxOEdrdmx4cjZFSEYzOGxFcDZRaVJVR2U3V1cxMms5aGozRU1JbEVFdUdRY1FxTkYzd2FiaEVxYk5DOU11bnRBdDRjeUF6?oc=5","date":"2022-10-26","type":"pipeline","source":"Fierce Pharma","summary":"Bone Therapeutics joins biotech name change rage, rebranding as BioSenic - Fierce Pharma","headline":"Bone Therapeutics joins biotech name change rage, rebranding as BioSenic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNV0stc0NydjhmU3JHSDFaeDFULVA4WFg0aURRUjc5a053bGVfaTBST3U4X2F0WGZlVmhyQjdwSHNXUGU4SWhyVWhaQVZaVk1PZXFfbkRJQ0kwR2JXMWFjVjJiTG9oYmZscWJJMTNHRHFkczJuX3RtdWhtX2x1U1dVSkxNSWxHYVdSSVVRbTdNbnktaGJtNkM3Q2xud0txYmNVV194VXhB?oc=5","date":"2022-10-25","type":"pipeline","source":"European Biotechnology Magazine","summary":"Bone Therapeutics merges with Medsenic and changes name - European Biotechnology Magazine","headline":"Bone Therapeutics merges with Medsenic and changes name","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}